128 related articles for article (PubMed ID: 26482680)
1. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.
Younossi Z; Brown A; Buti M; Fagiuoli S; Mauss S; Rosenberg W; Serfaty L; Srivastava A; Smith N; Stepanova M; Beckerman R
J Viral Hepat; 2016 Mar; 23(3):217-26. PubMed ID: 26482680
[TBL] [Abstract][Full Text] [Related]
2. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
Younossi ZM; Jiang Y; Smith NJ; Stepanova M; Beckerman R
Hepatology; 2015 May; 61(5):1471-8. PubMed ID: 25706754
[TBL] [Abstract][Full Text] [Related]
3. Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia.
Younossi ZM; Chan HLY; Dan YY; Lee MH; Lim YS; Kruger E; Tan SC
J Viral Hepat; 2018 Mar; 25(3):228-235. PubMed ID: 29053909
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
[TBL] [Abstract][Full Text] [Related]
5. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
Younossi ZM; Elsheikh E; Stepanova M; Gerber L; Nader F; Stamm LM; Brainard DM; McHutchinson JG
J Viral Hepat; 2015 Dec; 22(12):977-82. PubMed ID: 26280786
[TBL] [Abstract][Full Text] [Related]
6. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P
J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586
[TBL] [Abstract][Full Text] [Related]
7. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M
Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860
[TBL] [Abstract][Full Text] [Related]
8. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C.
Connolly MP; Kotsopoulos N; Ustianowski A
J Med Econ; 2018 Jan; 21(1):19-26. PubMed ID: 28830254
[TBL] [Abstract][Full Text] [Related]
9. Treating Medicaid patients with hepatitis C: clinical and economic impact.
Younossi Z; Gordon SC; Ahmed A; Dieterich D; Saab S; Beckerman R
Am J Manag Care; 2017 Feb; 23(2):107-112. PubMed ID: 28245654
[TBL] [Abstract][Full Text] [Related]
10. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
12. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
14. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
[TBL] [Abstract][Full Text] [Related]
15. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
Younossi ZM; Stepanova M; Marcellin P; Afdhal N; Kowdley KV; Zeuzem S; Hunt SL
Hepatology; 2015 Jun; 61(6):1798-808. PubMed ID: 25627448
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
[TBL] [Abstract][Full Text] [Related]
17. [Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment].
Stahmeyer JT; Rossol S; Bert F; Liersch S; Krauth C
Z Gastroenterol; 2016 Aug; 54(8):760-9. PubMed ID: 27529526
[TBL] [Abstract][Full Text] [Related]
18. Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials.
Messori A; Brunetto MR; De Luca A; Zignego AL
Dig Liver Dis; 2015 Nov; 47(11):988-9. PubMed ID: 26205830
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C.
Gamal N; Andreone P
Expert Opin Drug Saf; 2016; 15(4):549-57. PubMed ID: 26899025
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
